Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Seeks Details Of Antidepressant Suicide Data Evaluation By Columbia University

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Charles Grassley is requesting information on the "rationale" for a non-FDA review of the data. The request is part of an ongoing investigation of the agency's handling of suicide-related events in pediatric antidepressant data.

You may also be interested in...



FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators

Finance Committee staff continues its inquiry into how FDA handled information on a possible link between antidepressants and suicidality. A June 2 letter asks for contact information of former Office of Drug Safety employees and a list of meetings between CDER officials and manufacturers.

FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators

Finance Committee staff continues its inquiry into how FDA handled information on a possible link between antidepressants and suicidality. A June 2 letter asks for contact information of former Office of Drug Safety employees and a list of meetings between CDER officials and manufacturers.

FDA Antidepressant Data Was Fully Disclosed, Agency Tells Congress

Although there was internal disagreement on the implications of pediatric antidepressant data, all information was reviewed publicly, the agency maintains in a letter to the House Energy & Commerce/Oversight Subcommittee.

Related Content

Topics

UsernamePublicRestriction

Register

PS059393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel